This disclosure is related to condition and disease detection tools and related methods involving measurement of electrochemical osmolarity or osmolality.
Dry eye is often qualitatively diagnosed through mechanisms linked to tear production volume (Schirmer Test) and patient symptoms (irritation and inflammation). Tear composition plays an important role in the identification of the severity of this disease. The development and implementation of a device to quantify the salinity of tear fluid will complement the current practices of ophthalmologists and lead to improved treatment.
Moreover, many other conditions may be better assessed through the measurement of osmolarity or osmolality, such as dehydration based on serum osmolality. Accordingly, devices and methods that quantify the salinity of body fluid samples could find widespread application.
Some embodiments herein relate to apparatus and methods for dry eye detection and diagnosis, as well as other ocular diseases, through the electrochemical impedance measurement of tear fluid osmolarity. For example, tear fluid can be drawn to a custom electrode from the eye using FDA approved filter paper. A range of tear fluid osmolarity associated with dry eye can be detected in the tear fluid using Electrochemical Impedance Spectroscopy (EIS) in a handheld point-of-care device. Accordingly, the embodiments herein can help improve the quality of life and the management of ocular conditions such as dry eye by providing more accurate information for medical assessment and treatment.
Other embodiments relate to measurement of osmolarity or osmolality in various bodily fluids for the assessment of conditions, such as dehydration, or indications of disease.
Embodiments herein relate to apparatus and methods for condition or disease detection. For example, turning to
For example, treatment options may include punctal occlusion, meibomian gland therapy or some type of ocular medication (e.g., an anti-inflammatory topical). These medications include but are not limited to dozens of over-the-counter eye drops, or possibly prescription drugs like Restasis® (cyclosporine ophthalmic emulsion), Xiidra® (lifitegrast ophthalmic solution) or hydroxypropyl cellulose ophthalmic drops.
Further embodiments herein relate to the measurement of osmolarity or osmolality in fluids or secretions not in equilibrium with the extra-cellular fluids of the body, including but not limited to gastric juice, saliva and sweat. Serum osmolality is normally between 275 to 295 mOsm/kg; it increases with dehydration and decreases with over-hydration. Thus, a direct measurement of hydration levels is possible with measurement of serum osmolality. Dehydration can be treated with increased fluid intake, while increasing salts in the body (e.g., intravenously) can be used to treat over-hydration.
By way of example for embodiments that involve assessment of tear osmolarity, as shown in
Turning to
In all sensor embodiments, the sensor would be operably configured to utilize electrochemical impedance. For example, a power supply, computer/software, potentiostat, and/or further EIS components necessary for the sensor to operate/provide measurements are provided. Such EIS system components are available commercially through sources such as NuVant Systems.
In one embodiment, a sensor contains three electrodes (working, counter & reference). A 50% NaCl/50% ferricyanide [10 mM] (electron mediator) solution is applied to sensor and the applied voltage is −0.17 V with an amplitude of 5 mV and sweeping a range of frequencies from 1 to 100 k Hz. Resistance to electron flow to the sensor is measured at the range of frequencies. At the optimal frequency, the complex impedance can be correlated to the concentration of NaCl.
Advantageously, test results can obtained quickly (e.g., in under 90 seconds). Concentration measurements are taken at the optimal frequency of the system, providing the best resolution. Moreover, the system provides accurate readings over an extreme range of concentrations (3-30 mg/mL), and good results are obtained with a range of sample volumes between 5 and 100 uL, thereby indicating that the sensor is robust across volume changes. Furthermore, bare gold sensors may be used, without any sample preparation or employed filters on the sensor surface.
The results may be displayed on the device and/or an external device such as a phone or computer screen.
By way of further example, urinalysis through osmolarity measurement may provide useful assessment information:
Higher than Normal Measurements May Indicate:
Lower than Normal Measurements May Indicate:
Thus, methods and devices disclosed herein may be useful in the measurement of osmolarity and osmolality of a variety of body fluids and for a variety of conditions or diseases.
The claims are not meant to be limited to the materials, methods, embodiments, and examples described herein.
This application claims priority to U.S. Provisional Patent Application No. 62/455,913 filed on Feb. 7, 2017, the disclosure of which is incorporated herein in its entirety by reference.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2018/017158 | 2/7/2018 | WO | 00 |
Number | Date | Country | |
---|---|---|---|
62455913 | Feb 2017 | US |